Generic Name:
somapacitan
Project Status:
Pending
Therapeutic Area:
Growth Hormone Deficiency (GHD)
Manufacturer:
Novo Nordisk Canada Inc.
Call for patient/clinician input open:
Brand Name:
Sogroya
Project Line:
Reimbursement Review
Project Number:
SR0779-000
Call for patient/clinician input closed:
Details
Manufacturer Requested Reimbursement Criteria1:
The long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone (Growth Hormone Deficiency (GHD)).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
The long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone (Growth Hormone Deficiency (GHD)).
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.